{"analyses":[{"ciLowerLimit":"-32.78","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"-17.72","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"3.834","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","paramType":"Mean Difference (Final Values)","paramValue":"-25.25","statisticalMethod":"ANCOVA"},{"ciLowerLimit":"-51.33","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"-37.65","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"3.482","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","paramType":"Mean Difference (Final Values)","paramValue":"-44.49","statisticalMethod":"ANCOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.723","value":"-2.96"},{"groupId":"OG001","spread":"2.770","value":"-28.21"},{"groupId":"OG002","spread":"2.229","value":"-47.45"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"151"},{"groupId":"OG002","value":"230"}],"units":"Participants"}],"description":"SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes. Least Squares Mean (LSM) was calculated using analysis of covariance (ANCOVA) with geographic region duration of current episode at baseline (\\< 4 years versus ≥4 years), treatment group, and baseline value in the model.","dispersionType":"Standard Error","groups":[{"description":"Participants received two placebo tablets matched to baricitinib, administered orally QD to maintain the blind.","id":"OG000","title":"Placebo"},{"description":"Participants received one 2 mg Baricitinib tablet administered orally QD and one placebo tablet administered orally QD to maintain the blind.","id":"OG001","title":"2 mg Baricitinib"},{"description":"Participants received one 4 mg Baricitinib tablet and one placebo tablet administered orally QD to maintain the blind.","id":"OG002","title":"4 mg Baricitinib"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"All randomized participants with nonmissing baseline and at least one postbaseline measure who had evaluable data for this outcome measure. The method used to handle missing data was modified last observation carried forward (mLOCF) which used the most recent nonmissing postbaseline assessment.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 36","title":"Percent Change From Baseline in SALT Score at Week 36","type":"SECONDARY","unitOfMeasure":"percentage of change"}